The villains were injectable specialty drugs like Keytruda and inpatient surgical procedures for seriously ill patients.

Stephens analyst Scott Fidel lowered the firm’s price target on Cigna (CI) to $380 from $410 and keeps an Overweight rating on the shares. The ...

Cigna executives kicked off Thursday’s earnings call by responding to pharmacy benefit manager critics with a number of reforms.

Cigna has deleveraged substantially after acquiring Express Scripts in late 2018 when Cigna's debt rose to over $42 billion, or debt/capital of 51%. Management has made good progress on its ...

CEO David Cordani highlighted Cigna's full-year revenue growth of $247 billion, a 27% increase, alongside adjusted EPS of $27.33, which fell short of expectations. He reaffirmed the company's ...

Cigna forecast annual profit below Wall Street expectations on Thursday and missed estimates for the fourth quarter, hurt by higher medical costs for a type of employer-sponsored healthcare plan.